Navigation Links
NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump™ and ResQPOD® CPR Devices
Date:11/15/2010

CHICAGO, Nov. 15, 2010 /PRNewswire/ -- A combination of two devices could save the lives of several thousand cardiac arrest patients each year if implemented nationwide, suggests results of a clinical trial presented at today's American Heart Association Resuscitation Science Symposium. A significantly higher percentage of patients who experienced out-of-hospital cardiac arrest survived after receiving active compression decompression cardiopulmonary resuscitation (ACD CPR) performed with the ResQPump™ and the ResQPOD® impedance threshold device as compared to those receiving conventional, manual CPR performed with a pair of hands. Both devices are manufactured by Advanced Circulatory Systems, Inc. (ACSI) in Roseville, Minn.

Ralph J. Frascone, MD, associate professor of emergency medicine at the University of Minnesota and EMS medical director at Regions Hospital in St. Paul (Minn), presented the results of the study.

"Each year, approximately 300,000 Americans experience out-of-hospital cardiac arrest, and the national average for survival to hospital discharge is dismal – only about 5 percent," Frascone said. "However, in this study, patients who received CPR by rescuers using the device combination had a 53 percent higher survival to hospital discharge rate with favorable neurologic function than those who did not, and, a significant survival benefit was still present one year after the initial cardiac arrest event."

"The goal of resuscitation during cardiac arrest is long-term survival with preservation of brain function," commented Dr. Tom P. Aufderheide, principal investigator at one of the study sites. "This new, effective intervention achieves that goal and is potentially the most significant advancement in the treatment of cardiac arrest since defibrillation."

Funded by the National Institutes of Health and sponsored by Advanced Circulatory Systems, Inc., the trial compared survival rates among a control group of 813 cardiac arrest patients receiving standard CPR to an intervention group of 840 receiving ACD CPR, performed using the ResQPump, with an impedance threshold device (ITD), the ResQPOD. All other aspects of patient care, such as airway management, IV fluids, medications, defibrillation, resuscitation length, etc., were similar between the two groups. The randomized, prospective, multi-center trial was performed in seven distinct U.S. geographic locations, including 46 emergency medical services (EMS) agencies in urban, suburban, and rural areas serving a total population of 2.3 million.

"We are thrilled," said Keith G. Lurie, MD, chief medical officer of Advanced Circulatory Systems. "This was a huge undertaking, involving thousands of EMS providers and hospital personnel over a span of about five years. It is also the first prospective, randomized clinical trial to demonstrate a long-term survival benefit with favorable neurologic benefit using CPR devices."

The ResQPOD® is an impedance threshold device (ITD) that selectively prevents unnecessary respiratory gases from entering the chest during the chest wall recoil phase of CPR. It is attached within the ventilation circuit between the airway device and the ventilation source. By selectively restricting airflow during CPR, the device creates a small but important negative pressure (vacuum) in the chest that has been shown in numerous human and animal clinical trials to increase blood flow back to the patient's heart during CPR.

The ResQPump™ is a hand-held active compression decompression (ACD) CPR device placed in the same position on the sternum as the hands and enabling rescuers to perform similar chest compressions as in conventional CPR. Instead of allowing the chest wall to recoil passively, however, rescuers pull up on the ResQPump's handle with its suction cup. This provides active decompression of the chest, promotes optimal chest wall recoil and creates a negative intrathoracic pressure (vacuum) that helps return blood to the heart. The handle contains a force gauge and metronome that guide compression depth, recoil and rate. The ResQPump is identical to the CardioPump®, an ACD CPR device available for sale outside the U.S.

About ACSI

Advanced Circulatory Systems, Inc. is a privately held manufacturer of advanced circulatory technology based in Roseville, Minn. Its mission is to restore life and improve the quality of life for patients experiencing cardiac arrest, low blood pressure and head injury by developing new technologies to non-invasively increase circulation throughout the body, improving opportunities for survival and quality of life. The company manufactures and markets the ResQPOD, a version of which is currently available for sale and in use at more than 1,200 hospitals and EMS systems throughout the U.S.; and the CardioPump, which is currently available for sale only outside the U.S.


'/>"/>
SOURCE Advanced Circulatory Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
2. New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs
3. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
4. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
5. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
6. New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis
7. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
8. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
10. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
11. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... Ind. , Aug. 7, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that its Board of Directors has ... for the third quarter of 2017. ... be paid on or about October 27, 2017 to stockholders ... 22, 2017.  Future declarations of dividends are subject to approval ...
(Date:8/7/2017)... International plc (NASDAQ: ENDP ) today announced that ... U.S. mesh product liability claims and that it is ... claims at reasonable values. Under the agreements, Endo will ... 2017 and continuing through the fourth quarter of 2019. ... Company intends to increase its mesh product liability accrual ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... The Women’s Choice Award, a growing platform that gives a voice to ... Award. The identification by women of an effective new migraine relief product ... In a survey taken by the Women’s Choice Award organization, nine out of ten ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western North Carolina’s only ... popular international aesthetics conference for medical professionals about the positive impact Juliet™ ... his growing practice. , Dr. George K. Ibrahim shared the results ...
(Date:8/22/2017)... ... ... six years, Lightning Labels has sent out a call for users of its custom label ... of their designs. Submissions this year were open from May 18 to July 1 and ... of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... 2017 , ... Nurses at Apple Rehab Watch Hill , a nursing ... and certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... Centers for Medicare and Medicaid Services, to have a CPI machine that will provide ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “To Walk ... radioman on a B17 bomber named Edward Koontz. “To Walk Away” is the creation ... Scranton, who has published over two hundred manuscripts in chemistry and religion, as well ...
Breaking Medicine News(10 mins):